TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06216041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM-H014 ( FE)
Description: FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts sentinel method .The treatment in food effect consists of 2 periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ( FE)
Description: FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts sentinel method .The treatment in food effect consists of 2 periods.
Study: NCT05753254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Firefighting training exercises with no fire
Description: The participants will be performing firefighting equivalent work in a clean environment, without fire (no ambient temperature, soot or smoke).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Firefighting training exercises under wood fire
Description: The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models), under wood fire conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Firefighting training exercises under gas fire
Description: The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models), under gas fire conditions.
Study: NCT04767061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blockers
Description: The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blockers
Description: The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences.
Study: NCT06487637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CardioCare Quest
Description: CardioCare Quest will be the first telehealth game designed to enhance High Blood Pressure (HBP) treatment compliance and education about HBP, featuring a telemetry system that provides physicians and researchers data about sustainable healthy heart lifestyles beyond the clinic. The novelty of CardioCare Quest lies in its ability to compel HBP patients to playfully celebrate the mundane everyday practices that lead to sustainable habits and improved health outcomes using culturally sensitive and community-based design practices.
Study: NCT06448130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Henagliflozin 5mg
Description: Henagliflozin 5mg + lifestyle intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Henagliflozin 10mg
Description: Henagliflozin 10mg+ lifestyle intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo+ lifestyle intervention
Study: NCT04209023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Individual pulses (100% motor threshold intensity, continuous temperature of 24 degrees C) will be delivered upon the presentation of the stimulus or the verbal command for the language tasks. Two research coordinators will perform the intervention, with one coordinator presenting the stimulus/giving commands, and the other positioning the TMS coil and delivering the individual pulse or pulse trains. The stimulus presentation will last for a duration of 1 second, in conjunction with the time-course of the pulse's disruption. One or both research coordinators must track the successful or unsuccessful inhibition of task completion for each trial. The number of trials may vary depending on task and region-of-interest; however the intervention is not to exceed a total of 20 minutes.
Study: NCT05670639

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CAPABLE Care Partner
Description: The CAPABLE Care Partner intervention consists of three components: 1) up to 3 sessions with a Care Partner Support person focused on developing action plans for self-care goals of the care partner 2) educational materials provided in a folder at the beginning of the program 3) inclusion in the CAPABLE clinician visits as deemed appropriate by the client, CAPABLE clinicians, and care partner
Study: NCT04833335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI perfusion sequence
Description: Quantitative analysis
Study: NCT04615624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Furosemide, a loop diuretic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT05719779

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ronco-Onco and MAD
Description: Comparison of active over a neutral mandibular advacement oral appliance to assess tolerance and efficacy in oropharyngeal cancer individuals in managing snoring and sleep apnea following radiotherapy of oropharynx.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ronco-Onco and MAD
Description: Comparison of active over a neutral mandibular advacement oral appliance to assess tolerance and efficacy in oropharyngeal cancer individuals in managing snoring and sleep apnea following radiotherapy of oropharynx.
Study: NCT06307990

Intervention type: GENETIC
Intervention: NGS sequencing
Description: analysis of candidate genes for RTHs syndromes, transporters defects or gene involved in thyroid hormone metabolism. Whole exome sequencing (WES) in a minority of cases

Intervention type: DIAGNOSTIC_TEST
Intervention: serological tests
Description: assessment of T4, T3 and other TH metabolites (LC-MS) in serum and dried blood spots
Study: NCT05094063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient education by mobile application
Description: Training will be given to the patients in the experimental group.
Study: NCT04672980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTX-321
Description: RTX-321 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTX-321
Description: RTX-321 monotherapy
Study: NCT06343545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care provided by enrolling hospitals

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care provided by enrolling hospitals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: An implementation bundle of measures to improve outcomes in intensive care unit, hospital, and after hospital discharge, including rehabilitation at home performed through telemedicine.
Study: NCT04823728

Intervention type: GENETIC
Intervention: Autoimmune encephalitis and paraneoplastic neurological syndromes
Description: This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study.
Study: NCT05310461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement
Description: Early transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Deferred treatment, with intervention once AVA is ≤1.0 cm2 or if concomitant mitral regurgitation meets an indication for intervention
Description: Deferred transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement.
Study: NCT04962178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary PCI
Description: The patients assigned to early invasive strategy group will receive the primary PCI.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical therapy with primary PCI not performed
Description: The patients assigned to conservative strategy group will receive optimal medical therapy before primary endpoint accomplished.
Study: NCT04915144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATOC
Description: Subjects will receive 177Lu-DOTATOC PRRT treatment over 4 cycles, each cycle occurs every 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 177Lu-DOTATOC
Description: Subjects will receive 177Lu-DOTATOC PRRT treatment over 4 cycles, each cycle occurs every 8 weeks.
Study: NCT05018169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BA-A
Description: Session 1 focuses on the treatment rationale, structure, and expectations, and includes psychoeducation on depression. Session 2 focuses on working with parent(s) to help them support their teen through treatment. Session 3 focuses on the (situation)/behavior/feeling cycle and how teens individuals can get trapped in a cycle of depression and inactivity. Session 4 focuses on the assessment of values and choosing preferred activities to target. Session 5 focuses on teaching skills for in-person and electronic communication. Session 6 focuses on identifying barriers to treatment success. Session 7 focuses on teaching teens to handle disagreements. Session 8 focuses on the utilization of adaptive coping skills. Sessions 9-11 are meant to be used flexibly and should include review of any challenging concepts. Session 12 is the termination session and focuses on maintaining treatment gains. Between every session, teens will track their activity for homework.
Study: NCT04704687

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Children will perform two successive interventions composed each by a set of 15 sessions of effective-tDCS combine with cognitive-training exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Children will perform two successive interventions composed each by a set of 15 sessions of effective-tDCS combine with cognitive-training exercises.
Study: NCT05564208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elafibranor
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elafibranor
Description: Oral Tablet
Study: NCT05193877

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: autologous bone marrow aspirate concentrate by centrifugation
Description: 50 cc bone marrow aspirates concentrate after centrifugation with final volume up to 7 cc.~Assess total nucleated count and viability. Bone marrow aspirate concentrate is chosen as a source of mesenchymal stem cells, because of safe and easy procedure.~Bone marrow aspiration is done under local or general anesthesia, depending on the individual case. Around 50 cc of bone marrow is aspirated from the posterior iliac crest after proper sterilization using bone marrow aspiration needle (size according to the patient) and collected in heparinized syringes. Mononuclear cells (MNCs) are obtained by centrifugation. The isolated MNCs are checked for viability manually and confirmed on automated cell count machine.~The separated MNCs is administered intra-articularly immediately after centrifugation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous bone marrow aspirate concentrate by centrifugation
Description: 50 cc bone marrow aspirates concentrate after centrifugation with final volume up to 7 cc.~Assess total nucleated count and viability. Bone marrow aspirate concentrate is chosen as a source of mesenchymal stem cells, because of safe and easy procedure.~Bone marrow aspiration is done under local or general anesthesia, depending on the individual case. Around 50 cc of bone marrow is aspirated from the posterior iliac crest after proper sterilization using bone marrow aspiration needle (size according to the patient) and collected in heparinized syringes. Mononuclear cells (MNCs) are obtained by centrifugation. The isolated MNCs are checked for viability manually and confirmed on automated cell count machine.~The separated MNCs is administered intra-articularly immediately after centrifugation.
Study: NCT04683172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Direct Current Stimulation
Description: tDCS consists of delivering a low-intensity (1 to 2 milliamperes) direct electrical current by means of a pair of electrodes (anode and cathode) applied to the scalp. Electrodes generally have a diameter (round electrode) or a diagonal (rectangular electrodes) ranging from 2 to 3.5 cm.~To stimulate a given cortical zone, the anode is placed over of the selected zone, generally identified by means of an EEG headset (10/20 System Positioning). For the treatment of pain, the anode is placed over the primary motor cortex (M1) on the contralateral side to the pain or on the left side in patients with diffuse pain. The cathode is placed over a supposedly neutral cortical zone, usually the contralateral supraorbital cortex with respect to the anode. In this study, the stimulation intensity will be 1.5 mA using round sponge electrodes 3.5 cm in diameter.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: The tDCS device has a Sham mode that allows for true placebo stimulation. A simulated session is thus designed as a real stimulation session without its effects. Sensations similar to tDCS are created by generating currents only at the start of the session.~Same modalities as for the Active tDCS procedure will therefore be put in place: a pair of electrodes (anode and cathode) are applied to the scalp.To stimulate a given cortical zone, the anode is placed over of the selected zone, generally identified by means of an EEG headset (10/20 System Positioning). For the treatment of pain, the anode is placed over the primary motor cortex (M1) on the contralateral side to the pain or on the left side in patients with diffuse pain. The cathode is placed over a supposedly neutral cortical zone, usually the contralateral supraorbital cortex with respect to the anode.
Study: NCT05967052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT05270018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacterial Lysates
Description: 14mg once a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 14.0ml once a day
Study: NCT05006976

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NSAC health only
Description: NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health only, clinicians are provided survey information on potential health problems only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NSAC health + MBW
Description: NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health + MBW clinicians are provided survey information on potential health problems as well as information on motivation for work, barriers for return to work and work environment factors.
Study: NCT05967052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gradual movement therapy in the ward
Description: Gradual movement therapy in the ward

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gradual movement therapy in the ward
Description: Gradual movement therapy in the ward

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Telerehabilitation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Telerehabilitation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychotherapy
Study: NCT01454271

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty Replacement
Description: Total Hip Arthroplasty Replacement
Study: NCT06052930

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HTC Vive™ Pro
Description: A commercially available head-mounted display. Each VR session has approximately 20 minutes, performed 3 times per week.~Both groups maintain similar PD specialized physiotherapy sessions throughout the duration of the study (3 times per week, 60 minutes per session).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HTC Vive™ Pro
Description: A commercially available head-mounted display. Each VR session has approximately 20 minutes, performed 3 times per week.~Both groups maintain similar PD specialized physiotherapy sessions throughout the duration of the study (3 times per week, 60 minutes per session).
Study: NCT05405218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTR-US
Description: Carpal Tunnel Release with Ultrasound Guidance
Study: NCT03577418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician-facilitated educational intervention
Description: People with dementia (PWD) will complete the Preferences for Everyday Living (PELI). Care partners will complete the PELI from the perspective of the PWD (i.e., as if acting as surrogate decision-makers). Research staff will then review these assessments, highlighting areas of discrepancy in the importance of various preferences. A 30-minute preferences-based discussion will then be facilitated by the research clinician. This discussion will include review of the discrepancies identified in the assessments. The PWD and the care partners will then be encouraged to identify one area of discrepancy and to come together with a concrete action plan to resolve that area of discrepancy. A standardized document describing neuropsychiatric symptoms and reviewing the unmet needs hypothesis will be discussed with PWD and the care partners.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: In addition to the usual clinical care, the standardized document describing NPS and reviewing the unmet needs hypothesis will be given to the PWD and the care partner to review.
Study: NCT05405218

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mOCTR
Description: Mini Open Carpal Tunnel Release
Study: NCT04930146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture and bloodletting
Description: bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture and bloodletting
Description: bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.
Study: NCT05600985

Intervention type: PROCEDURE
Intervention: FS-LASIK
Description: Laser-assisted in situ keratomileusis, commonly referred to laser eye surgery or laser vision correction, is a type of refractive surgery for the correction of myopia, hypermetropia, and astigmatism.